Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The FEBS Journal|January 22, 2010
Crystal structure of the halotolerant gamma-glutamyltranspeptidase from Bacillus subtilis in complex with glutamate reveals a unique architecture of the solvent-exposed catalytic pocketKei Wada, Machiko Irie, Hideyuki Suzuki, et al.
Chemical & Pharmaceutical Bulletin|November 3, 2016
Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD)Terushige Muraoka, Mitsuaki Ide, Machiko Irie, et al.
Journal of Molecular Biology|June 17, 2008
Crystal structures of Escherichia coli gamma-glutamyltranspeptidase in complex with azaserine and acivicin: novel mechanistic implication for inhibition by glutamine antagonistsKei Wada, Jun Hiratake, Machiko Irie, et al.
Bioorganic & Medicinal Chemistry|July 25, 2016
Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD)Terushige Muraoka, Mitsuaki Ide, Kenji Morikami, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2012
Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitorsTakashi Chiba, Jun Ohwada, Hiroshi Sakamoto, et al.
Journal of the American Chemical Society|July 18, 2023
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS InhibitorMikimasa Tanada, Minoru Tamiya, Atsushi Matsuo, et al.
Bioorganic & Medicinal Chemistry|July 9, 2024
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA displayMirai Kage, Ryuji Hayashi, Atsushi Matsuo, et al.
Nature Communications|December 22, 2023
Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac diseaseYuu Okura, Yuri Ikawa-Teranishi, Akihiko Mizoroki, et al.
Scientific Reports|April 26, 2017
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseasesTaku Fukuzawa, Zenjiro Sampei, Kenta Haraya, et al.
Journal of the American Chemical Society|October 24, 2023
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough TargetsAtsushi Ohta, Mikimasa Tanada, Shojiro Shinohara, et al.
Pageof 1